The FDA will hus­tle up an ex­pe­dit­ed re­view for As­traZeneca’s next shot at a block­buster can­cer drug fran­chise

As­traZeneca paid a hefty price to part­ner with Dai­ichi Sankyo on their ex­per­i­men­tal an­ti­body drug con­ju­gate for HER2 pos­i­tive breast can­cer. And they’ve been re­ward­ed with a fast ride through the FDA, with a straight shot at cre­at­ing an­oth­er block­buster on­col­o­gy fran­chise.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER